Source of stem cell rescue: bone marrow versus peripheral blood progenitors. 1993

S F Williams, and T Zimmerman, and G Grad, and R Mick
Department of Medicine, University of Chicago Medical Center, IL 60637.

Sustained hematopoiesis can be restored after dose-intensive chemotherapy utilizing stem cells from either bone marrow and/or peripheral blood. Numerous reports have demonstrated the effectiveness of peripheral blood progenitors (PBPC) in restoring hematopoiesis. Here, we review data comparing the recovery among patients rescued with various stem cell sources after dose-intensive therapy. PBPC used alone or to augment autologous bone marrow to achieve timely hematopoietic recovery after dose-intensive therapy can result in shortened hospital stays, decreased transfusion requirements, and antibiotic usage. This will lead to increased application of dose-intensive therapy either singly or in multiple courses to treat various malignancies.

UI MeSH Term Description Entries
D007937 Leukapheresis The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor. Leukocytapheresis,Leukopheresis,Lymphapheresis,Lymphocytapheresis,Leukocytopheresis,Lymphocytopheresis,Lymphopheresis,Leukaphereses,Leukocytaphereses,Leukocytophereses,Leukophereses,Lymphaphereses,Lymphocytaphereses,Lymphocytophereses,Lymphophereses
D001773 Blood Cells The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM. Blood Corpuscles,Blood Cell,Blood Corpuscle,Cell, Blood,Cells, Blood,Corpuscle, Blood,Corpuscles, Blood
D001804 Blood Transfusion, Autologous Reinfusion of blood or blood products derived from the patient's own circulation. (Dorland, 27th ed) Autotransfusion,Autologous Blood Transfusion,Autologous Blood Transfusions,Blood Transfusions, Autologous,Transfusion, Autologous Blood,Transfusions, Autologous Blood,Autotransfusions
D001854 Bone Marrow Cells Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells. Bone Marrow Cell,Cell, Bone Marrow,Cells, Bone Marrow,Marrow Cell, Bone,Marrow Cells, Bone
D001855 Bone Marrow Diseases Diseases involving the BONE MARROW. Bone Marrow Disease,Disease, Bone Marrow,Diseases, Bone Marrow,Marrow Disease, Bone,Marrow Diseases, Bone
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002641 Chicago A city in Illinois.
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females

Related Publications

S F Williams, and T Zimmerman, and G Grad, and R Mick
January 2013, The New England journal of medicine,
S F Williams, and T Zimmerman, and G Grad, and R Mick
January 2013, The New England journal of medicine,
S F Williams, and T Zimmerman, and G Grad, and R Mick
March 2008, JPMA. The Journal of the Pakistan Medical Association,
S F Williams, and T Zimmerman, and G Grad, and R Mick
December 2000, Annals of hematology,
S F Williams, and T Zimmerman, and G Grad, and R Mick
January 1993, Lancet (London, England),
S F Williams, and T Zimmerman, and G Grad, and R Mick
January 2013, Blood,
S F Williams, and T Zimmerman, and G Grad, and R Mick
January 2009, Hematology/oncology and stem cell therapy,
S F Williams, and T Zimmerman, and G Grad, and R Mick
January 1992, Journal of hematotherapy,
S F Williams, and T Zimmerman, and G Grad, and R Mick
August 2016, Future oncology (London, England),
Copied contents to your clipboard!